Propranolol, Carvedilol and Rosuvastatin in the Prevention of Variceal Bleeding in Cirrhotic Portal Hypertension
Status:
Recruiting
Trial end date:
2022-12-20
Target enrollment:
Participant gender:
Summary
Patients with hepatic cirrhosis and previous variceal bleeding will be randomly assigned to
use propranolol or carvedilol. After 8 weeks, rosuvastatin or placebo will be blindly added
to nonresponders (HVPG measurement > 12mmHg) for another 8 weeks and hemodynamic response
will be assessed again.
Surrogate serum markers of portal hypertension will be evaluated and correlated to HVPG
values and to its variations.